Diabeties
-
Press Releases
Abbott’s FreeStyle Libre® 3 Receives U.S. FDA Clearance – Features World’s Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor
Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older6 living with diabetes. “The FreeStyle Libre 3 system is a direct result of listening to our customers – and giving them the innovation and sensing technology they’ve been looking for,” said Jared Watkin, senior vice president of Abbott’s…
Read More » -
Press Releases
Dexcom G6 Continuous Glucose Monitoring (CGM) System Receives CE Marking in Europe for Wear on Back of the Upper Arm
EDINBURGH, Scotland, June 9, 2020 /PRNewswire/ — DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received CE Marking across Europe, for wear on the back of the upper arm, providing patients more choice on how to comfortably wear their device. The Dexcom G6 uses a small, wearable sensor and transmitter to continuously measure and…
Read More » -
Press Releases
Orpyx® launches Orpyx SI Sensory Insoles with Remote Patient Monitoring to Prevent Diabetic Foot Ulcers
CALGARY, Alberta, Dec. 4, 2019 /PRNewswire/ — Orpyx® Medical Technologies Inc. (Orpyx), an innovator in digital health therapeutics, announced the launch of Orpyx SI Sensory Insoles with Remote Patient Monitoring for the prevention of diabetic foot ulcers (DFU) and neuropathy-related ulcers. By monitoring pressure, temperature, and movement, the Orpyx SI Sensory Insole system provides the wearer with real-time audiovisual alerts and allows them to immediately take action to resolve high-pressure areas that…
Read More » -
Press Releases
Dramatic A1c Improvement Among People with Diabetes Using One Drop | Mobile app on iPhone and Apple Watch
NEW YORK, Nov. 29, 2017 /PRNewswire/ — A study published in JMIR mHealth & uHealth found people with diabetes using the One Drop | Mobile app on their iPhone and Apple Watch reduce their hemoglobin A1c by an average 1.36%. Lowering A1c by an absolute 0.5% decreases cardiovascular disease by 10%. Each 1% A1c reduction is associated with a 37% decrease in the risk of…
Read More »